Effect of atorvastatin on humoral immune response to 23-valent pneumococcal polysaccharide vaccination in healthy volunteers: The StatVax randomized clinical trial
•First trial on the impact of statins on pneumococcal polysaccharide vaccination.•Atorvastatin enhanced total pneumococcal-specific antibody response by 41.5%.•Atorvastatin enhanced primary humoral immunity to T cell-independent vaccination.•Statins may be a novel vaccine adjuvant. The immunomodulat...
Saved in:
| Published in | Vaccine Vol. 37; no. 10; pp. 1313 - 1324 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Ltd
28.02.2019
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0264-410X 1873-2518 1873-2518 |
| DOI | 10.1016/j.vaccine.2019.01.023 |
Cover
| Abstract | •First trial on the impact of statins on pneumococcal polysaccharide vaccination.•Atorvastatin enhanced total pneumococcal-specific antibody response by 41.5%.•Atorvastatin enhanced primary humoral immunity to T cell-independent vaccination.•Statins may be a novel vaccine adjuvant.
The immunomodulatory effects of statins on vaccine response remain uncertain. Therefore, the objective of this study was to determine if atorvastatin enhances pneumococcal-specific antibody titer following 23-valent pneumococcal polysaccharide vaccination.
Double-blind, placebo-controlled, single-center randomized clinical trial entitled StatVax. Subjects were enrolled between June and July 2014 and followed up through September 2014. 33 healthy volunteers signed informed consent after volunteer sampling. 11 participants were excluded; 22 healthy volunteers without prior pneumococcal vaccination were enrolled and completed the study. Participants were randomized to receive a 28-day course of 40 mg atorvastatin (n = 12) or matching lactose placebo (n = 10). On day 7 of treatment, Pneumovax 23 was administered intramuscularly. The primary outcome was fold change in total pneumococcal-specific antibody titer determined by a ratio of post-vaccination titer over baseline titer. Secondary outcomes included serotype-specific pneumococcal antibody titer, seroconversion, complete blood counts (CBC), erythrocyte sedimentation rate (ESR), and serum cytokine analysis.
Of the 22 randomized patients (mean age, 23.86; SD, 4.121; 11 women [50%]), 22 completed the trial. Total anti-pneumococcal antibody titer in the atorvastatin group went from a baseline mean of 32.58 (SD, 15.96) to 147.7 (SD, 71.52) μg/mL at 21 days post-vaccination while titer in the placebo group went from a mean of 30.81 (SD, 13.04) to 104.4 (SD, 45) μg/mL. When comparing fold change between treatment groups, there was a significant increase in fold change of total anti-pneumococcal antibody titer in the atorvastatin group compared to the placebo group (2-way ANOVA, p = .0177).
Atorvastatin enhances antigen-specific primary humoral immune response to a T cell-independent pneumonia vaccination. Pending confirmation by larger cohort studies of target populations, peri-vaccination conventional doses of statins can become a novel adjuvant for poorly-immunogenic polysaccharide-based vaccines.
Trial Registration: clinicaltrials.gov Identifier: NCT02097589 |
|---|---|
| AbstractList | BackgroundThe immunomodulatory effects of statins on vaccine response remain uncertain. Therefore, the objective of this study was to determine if atorvastatin enhances pneumococcal-specific antibody titer following 23-valent pneumococcal polysaccharide vaccination.MethodsDouble-blind, placebo-controlled, single-center randomized clinical trial entitled StatVax. Subjects were enrolled between June and July 2014 and followed up through September 2014. 33 healthy volunteers signed informed consent after volunteer sampling. 11 participants were excluded; 22 healthy volunteers without prior pneumococcal vaccination were enrolled and completed the study. Participants were randomized to receive a 28-day course of 40 mg atorvastatin (n = 12) or matching lactose placebo (n = 10). On day 7 of treatment, Pneumovax 23 was administered intramuscularly. The primary outcome was fold change in total pneumococcal-specific antibody titer determined by a ratio of post-vaccination titer over baseline titer. Secondary outcomes included serotype-specific pneumococcal antibody titer, seroconversion, complete blood counts (CBC), erythrocyte sedimentation rate (ESR), and serum cytokine analysis.ResultsOf the 22 randomized patients (mean age, 23.86; SD, 4.121; 11 women [50%]), 22 completed the trial. Total anti-pneumococcal antibody titer in the atorvastatin group went from a baseline mean of 32.58 (SD, 15.96) to 147.7 (SD, 71.52) μg/mL at 21 days post-vaccination while titer in the placebo group went from a mean of 30.81 (SD, 13.04) to 104.4 (SD, 45) μg/mL. When comparing fold change between treatment groups, there was a significant increase in fold change of total anti-pneumococcal antibody titer in the atorvastatin group compared to the placebo group (2-way ANOVA, p = .0177).ConclusionsAtorvastatin enhances antigen-specific primary humoral immune response to a T cell-independent pneumonia vaccination. Pending confirmation by larger cohort studies of target populations, peri-vaccination conventional doses of statins can become a novel adjuvant for poorly-immunogenic polysaccharide-based vaccines.Trial Registration: clinicaltrials.gov Identifier: NCT02097589 The immunomodulatory effects of statins on vaccine response remain uncertain. Therefore, the objective of this study was to determine if atorvastatin enhances pneumococcal-specific antibody titer following 23-valent pneumococcal polysaccharide vaccination. Double-blind, placebo-controlled, single-center randomized clinical trial entitled StatVax. Subjects were enrolled between June and July 2014 and followed up through September 2014. 33 healthy volunteers signed informed consent after volunteer sampling. 11 participants were excluded; 22 healthy volunteers without prior pneumococcal vaccination were enrolled and completed the study. Participants were randomized to receive a 28-day course of 40 mg atorvastatin (n = 12) or matching lactose placebo (n = 10). On day 7 of treatment, Pneumovax 23 was administered intramuscularly. The primary outcome was fold change in total pneumococcal-specific antibody titer determined by a ratio of post-vaccination titer over baseline titer. Secondary outcomes included serotype-specific pneumococcal antibody titer, seroconversion, complete blood counts (CBC), erythrocyte sedimentation rate (ESR), and serum cytokine analysis. Of the 22 randomized patients (mean age, 23.86; SD, 4.121; 11 women [50%]), 22 completed the trial. Total anti-pneumococcal antibody titer in the atorvastatin group went from a baseline mean of 32.58 (SD, 15.96) to 147.7 (SD, 71.52) μg/mL at 21 days post-vaccination while titer in the placebo group went from a mean of 30.81 (SD, 13.04) to 104.4 (SD, 45) μg/mL. When comparing fold change between treatment groups, there was a significant increase in fold change of total anti-pneumococcal antibody titer in the atorvastatin group compared to the placebo group (2-way ANOVA, p = .0177). Atorvastatin enhances antigen-specific primary humoral immune response to a T cell-independent pneumonia vaccination. Pending confirmation by larger cohort studies of target populations, peri-vaccination conventional doses of statins can become a novel adjuvant for poorly-immunogenic polysaccharide-based vaccines. clinicaltrials.gov Identifier: NCT02097589. •First trial on the impact of statins on pneumococcal polysaccharide vaccination.•Atorvastatin enhanced total pneumococcal-specific antibody response by 41.5%.•Atorvastatin enhanced primary humoral immunity to T cell-independent vaccination.•Statins may be a novel vaccine adjuvant. The immunomodulatory effects of statins on vaccine response remain uncertain. Therefore, the objective of this study was to determine if atorvastatin enhances pneumococcal-specific antibody titer following 23-valent pneumococcal polysaccharide vaccination. Double-blind, placebo-controlled, single-center randomized clinical trial entitled StatVax. Subjects were enrolled between June and July 2014 and followed up through September 2014. 33 healthy volunteers signed informed consent after volunteer sampling. 11 participants were excluded; 22 healthy volunteers without prior pneumococcal vaccination were enrolled and completed the study. Participants were randomized to receive a 28-day course of 40 mg atorvastatin (n = 12) or matching lactose placebo (n = 10). On day 7 of treatment, Pneumovax 23 was administered intramuscularly. The primary outcome was fold change in total pneumococcal-specific antibody titer determined by a ratio of post-vaccination titer over baseline titer. Secondary outcomes included serotype-specific pneumococcal antibody titer, seroconversion, complete blood counts (CBC), erythrocyte sedimentation rate (ESR), and serum cytokine analysis. Of the 22 randomized patients (mean age, 23.86; SD, 4.121; 11 women [50%]), 22 completed the trial. Total anti-pneumococcal antibody titer in the atorvastatin group went from a baseline mean of 32.58 (SD, 15.96) to 147.7 (SD, 71.52) μg/mL at 21 days post-vaccination while titer in the placebo group went from a mean of 30.81 (SD, 13.04) to 104.4 (SD, 45) μg/mL. When comparing fold change between treatment groups, there was a significant increase in fold change of total anti-pneumococcal antibody titer in the atorvastatin group compared to the placebo group (2-way ANOVA, p = .0177). Atorvastatin enhances antigen-specific primary humoral immune response to a T cell-independent pneumonia vaccination. Pending confirmation by larger cohort studies of target populations, peri-vaccination conventional doses of statins can become a novel adjuvant for poorly-immunogenic polysaccharide-based vaccines. Trial Registration: clinicaltrials.gov Identifier: NCT02097589 The immunomodulatory effects of statins on vaccine response remain uncertain. Therefore, the objective of this study was to determine if atorvastatin enhances pneumococcal-specific antibody titer following 23-valent pneumococcal polysaccharide vaccination.BACKGROUNDThe immunomodulatory effects of statins on vaccine response remain uncertain. Therefore, the objective of this study was to determine if atorvastatin enhances pneumococcal-specific antibody titer following 23-valent pneumococcal polysaccharide vaccination.Double-blind, placebo-controlled, single-center randomized clinical trial entitled StatVax. Subjects were enrolled between June and July 2014 and followed up through September 2014. 33 healthy volunteers signed informed consent after volunteer sampling. 11 participants were excluded; 22 healthy volunteers without prior pneumococcal vaccination were enrolled and completed the study. Participants were randomized to receive a 28-day course of 40 mg atorvastatin (n = 12) or matching lactose placebo (n = 10). On day 7 of treatment, Pneumovax 23 was administered intramuscularly. The primary outcome was fold change in total pneumococcal-specific antibody titer determined by a ratio of post-vaccination titer over baseline titer. Secondary outcomes included serotype-specific pneumococcal antibody titer, seroconversion, complete blood counts (CBC), erythrocyte sedimentation rate (ESR), and serum cytokine analysis.METHODSDouble-blind, placebo-controlled, single-center randomized clinical trial entitled StatVax. Subjects were enrolled between June and July 2014 and followed up through September 2014. 33 healthy volunteers signed informed consent after volunteer sampling. 11 participants were excluded; 22 healthy volunteers without prior pneumococcal vaccination were enrolled and completed the study. Participants were randomized to receive a 28-day course of 40 mg atorvastatin (n = 12) or matching lactose placebo (n = 10). On day 7 of treatment, Pneumovax 23 was administered intramuscularly. The primary outcome was fold change in total pneumococcal-specific antibody titer determined by a ratio of post-vaccination titer over baseline titer. Secondary outcomes included serotype-specific pneumococcal antibody titer, seroconversion, complete blood counts (CBC), erythrocyte sedimentation rate (ESR), and serum cytokine analysis.Of the 22 randomized patients (mean age, 23.86; SD, 4.121; 11 women [50%]), 22 completed the trial. Total anti-pneumococcal antibody titer in the atorvastatin group went from a baseline mean of 32.58 (SD, 15.96) to 147.7 (SD, 71.52) μg/mL at 21 days post-vaccination while titer in the placebo group went from a mean of 30.81 (SD, 13.04) to 104.4 (SD, 45) μg/mL. When comparing fold change between treatment groups, there was a significant increase in fold change of total anti-pneumococcal antibody titer in the atorvastatin group compared to the placebo group (2-way ANOVA, p = .0177).RESULTSOf the 22 randomized patients (mean age, 23.86; SD, 4.121; 11 women [50%]), 22 completed the trial. Total anti-pneumococcal antibody titer in the atorvastatin group went from a baseline mean of 32.58 (SD, 15.96) to 147.7 (SD, 71.52) μg/mL at 21 days post-vaccination while titer in the placebo group went from a mean of 30.81 (SD, 13.04) to 104.4 (SD, 45) μg/mL. When comparing fold change between treatment groups, there was a significant increase in fold change of total anti-pneumococcal antibody titer in the atorvastatin group compared to the placebo group (2-way ANOVA, p = .0177).Atorvastatin enhances antigen-specific primary humoral immune response to a T cell-independent pneumonia vaccination. Pending confirmation by larger cohort studies of target populations, peri-vaccination conventional doses of statins can become a novel adjuvant for poorly-immunogenic polysaccharide-based vaccines.CONCLUSIONSAtorvastatin enhances antigen-specific primary humoral immune response to a T cell-independent pneumonia vaccination. Pending confirmation by larger cohort studies of target populations, peri-vaccination conventional doses of statins can become a novel adjuvant for poorly-immunogenic polysaccharide-based vaccines.clinicaltrials.gov Identifier: NCT02097589.TRIAL REGISTRATIONclinicaltrials.gov Identifier: NCT02097589. The immunomodulatory effects of statins on vaccine response remain uncertain. Therefore, the objective of this study was to determine if atorvastatin enhances pneumococcal-specific antibody titer following 23-valent pneumococcal polysaccharide vaccination.Double-blind, placebo-controlled, single-center randomized clinical trial entitled StatVax. Subjects were enrolled between June and July 2014 and followed up through September 2014. 33 healthy volunteers signed informed consent after volunteer sampling. 11 participants were excluded; 22 healthy volunteers without prior pneumococcal vaccination were enrolled and completed the study. Participants were randomized to receive a 28-day course of 40 mg atorvastatin (n = 12) or matching lactose placebo (n = 10). On day 7 of treatment, Pneumovax 23 was administered intramuscularly. The primary outcome was fold change in total pneumococcal-specific antibody titer determined by a ratio of post-vaccination titer over baseline titer. Secondary outcomes included serotype-specific pneumococcal antibody titer, seroconversion, complete blood counts (CBC), erythrocyte sedimentation rate (ESR), and serum cytokine analysis.Of the 22 randomized patients (mean age, 23.86; SD, 4.121; 11 women [50%]), 22 completed the trial. Total anti-pneumococcal antibody titer in the atorvastatin group went from a baseline mean of 32.58 (SD, 15.96) to 147.7 (SD, 71.52) μg/mL at 21 days post-vaccination while titer in the placebo group went from a mean of 30.81 (SD, 13.04) to 104.4 (SD, 45) μg/mL. When comparing fold change between treatment groups, there was a significant increase in fold change of total anti-pneumococcal antibody titer in the atorvastatin group compared to the placebo group (2-way ANOVA, p = .0177).Atorvastatin enhances antigen-specific primary humoral immune response to a T cell-independent pneumonia vaccination. Pending confirmation by larger cohort studies of target populations, peri-vaccination conventional doses of statins can become a novel adjuvant for poorly-immunogenic polysaccharide-based vaccines.Trial Registration: clinicaltrials.gov Identifier: NCT02097589 |
| Author | Wildes, Tyler J. Brantly, Mark Fasanya, Henrietta Dyson, Kyle A. Grippin, Adam |
| AuthorAffiliation | 4 University of Florida Division of Pulmonary and Critical Care Medicine, Gainesville, FL, USA 2 University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA 3 University of Florida Health Cancer Center, Department of Radiation Oncology, Gainesville, FL, USA 1 University of Florida MD-PhD Program, College of Medicine, Gainesville, FL, USA |
| AuthorAffiliation_xml | – name: 4 University of Florida Division of Pulmonary and Critical Care Medicine, Gainesville, FL, USA – name: 2 University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA – name: 1 University of Florida MD-PhD Program, College of Medicine, Gainesville, FL, USA – name: 3 University of Florida Health Cancer Center, Department of Radiation Oncology, Gainesville, FL, USA |
| Author_xml | – sequence: 1 givenname: Tyler J. orcidid: 0000-0001-8313-9144 surname: Wildes fullname: Wildes, Tyler J. email: twildes@ufl.edu organization: University of Florida MD-PhD Program, College of Medicine, Gainesville, FL, USA – sequence: 2 givenname: Adam surname: Grippin fullname: Grippin, Adam organization: University of Florida MD-PhD Program, College of Medicine, Gainesville, FL, USA – sequence: 3 givenname: Henrietta surname: Fasanya fullname: Fasanya, Henrietta organization: University of Florida MD-PhD Program, College of Medicine, Gainesville, FL, USA – sequence: 4 givenname: Kyle A. surname: Dyson fullname: Dyson, Kyle A. organization: University of Florida MD-PhD Program, College of Medicine, Gainesville, FL, USA – sequence: 5 givenname: Mark surname: Brantly fullname: Brantly, Mark organization: University of Florida MD-PhD Program, College of Medicine, Gainesville, FL, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30686636$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNksuO0zAUhi00iOkMPALIEhs2Kb4krgMChEbDRRqJBQNiZ7nOCXFJ7GI7EeV1eFFc2hlBN2WTLPL9X459_jN04rwDhB5SMqeEiqer-aSNsQ7mjNB6TuicMH4Hzahc8IJVVJ6gGWGiLEpKvpyisxhXhJCK0_oeOuVESCG4mKFfl20LJmHfYp18mHRMOlmHvcPdOPige2yHYXSAA8S1dxFw8pjxYtI9uITXDjJmvDGZXPt-E_NUnQ62AbwbMOuyLCs70H3qNnjy_egSQIjP8HUH-GP-42f9AwftGj_Yn9Bg01tnt8YUrO7vo7ut7iM82L_P0ac3l9cX74qrD2_fX7y-KkwlWSpoa5Yl1LAsSxCiqSTX1fYhBBO1NITyCkAbSYWmJaXQMk6Z0Ia3sq3apebn6OXOux6XAzQmny-fX62DHXTYKK-t-veLs5366icl-KKmlGTBk70g-O8jxKQGGw30vXbgx6gYY5SwqqrlcZQu6nLBF7LO6OMDdOXH4PJNZEoSyStWs0w9-nv426lvVp2BageY4GMM0N4ilKhtpdRK7SultpVShKpcqZx7fpAzNv1Zar4D2x9Nv9qlIS9ushBUNBacgcaG3DvVeHvU8OLAcNOOb7D5j_xvgyQD1A |
| CitedBy_id | crossref_primary_10_1093_cid_ciaa1384 crossref_primary_10_1093_oxfimm_iqaa001 crossref_primary_10_1007_s40266_023_01075_9 crossref_primary_10_1172_jci_insight_136141 crossref_primary_10_1186_s12979_024_00476_7 crossref_primary_10_1080_14787210_2021_1834848 |
| Cites_doi | 10.1592/phco.27.3.325 10.1093/infdis/jir695 10.1111/j.1365-2249.2011.04473.x 10.1001/jama.2015.13766 10.1038/82219 10.1001/jama.286.1.64 10.1111/j.1365-2567.2006.02505.x 10.1002/clc.22577 10.4049/jimmunol.200.Supp.167.19 10.4049/jimmunol.198.Supp.67.10 10.1016/j.atherosclerosis.2004.02.016 10.2337/db14-1059 10.1182/blood-2007-08-106005 10.1016/S0140-6736(09)61204-6 10.1155/2017/5642704 10.3399/bjgp11X606654 10.7326/M17-3439 10.1016/j.jaci.2012.07.002 10.1073/pnas.0508492103 10.1016/j.atherosclerosis.2007.07.031 10.1086/529197 10.1136/thx.2006.062885 10.4049/jimmunol.1501932 10.1016/j.vaccine.2005.12.042 10.1016/j.molimm.2007.12.008 10.1056/NEJMoa022678 10.1189/jlb.0202075 10.1161/01.CIR.0000103624.14436.4B 10.1371/journal.pone.0092095 10.1111/j.1365-2567.2011.03530.x 10.1016/j.vaccine.2006.03.088 10.2105/AJPH.90.2.223 10.1161/01.CIR.101.2.207 10.1001/jama.2013.280031 10.1007/s00228-003-0668-1 10.1038/nature01158 10.4049/jimmunol.176.9.5284 10.1001/archinte.168.19.2081 10.1056/NEJMoa1209165 10.1001/jama.2015.15629 |
| ContentType | Journal Article |
| Copyright | 2019 The Authors Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved. Copyright Elsevier Limited Feb 28, 2019 |
| Copyright_xml | – notice: 2019 The Authors – notice: Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved. – notice: Copyright Elsevier Limited Feb 28, 2019 |
| DBID | 6I. AAFTH AAYXX CITATION NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 7S9 L.6 5PM |
| DOI | 10.1016/j.vaccine.2019.01.023 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Korea ProQuest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Biological Science Collection Consumer Health Database Health & Medical Collection (Alumni) Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | Research Library Prep PubMed MEDLINE - Academic AGRICOLA |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-2518 |
| EndPage | 1324 |
| ExternalDocumentID | PMC6379110 30686636 10_1016_j_vaccine_2019_01_023 S0264410X19300775 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCATS NIH HHS grantid: TL1 TR001428 – fundername: NCATS NIH HHS grantid: UL1 TR001427 |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ACDAQ ACGFO ACGFS ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGGSO AGUBO AGYEJ AHMBA AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- 3V. 6I. AACTN AAFTH AAIAV ABLVK ABYKQ AESVU AFCTW AFKWA AJOXV AMFUW EFLBG LCYCR QYZTP RIG .GJ 29Q AAQXK AAYXX ABWVN ABXDB ACMHX ACRPL ADMUD ADNMO ADSLC ADVLN AFJKZ AGHFR AGQPQ AGRNS AGWPP AHHHB AIGII ALIPV ASPBG AVWKF AZFZN CITATION FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- SAE SEW SIN SVS WUQ XPP ZGI ZXP NPM 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 7S9 L.6 5PM |
| ID | FETCH-LOGICAL-c582t-1fcb4e9eb44e66d583a5583a662698c0135eeac816a1411ef23126ac3f8f5fba3 |
| IEDL.DBID | 7X7 |
| ISSN | 0264-410X 1873-2518 |
| IngestDate | Thu Aug 21 18:15:43 EDT 2025 Thu Sep 04 15:57:02 EDT 2025 Thu Sep 04 21:36:16 EDT 2025 Wed Aug 13 06:23:33 EDT 2025 Wed Feb 19 02:30:56 EST 2025 Thu Apr 24 22:59:06 EDT 2025 Tue Jul 01 01:06:45 EDT 2025 Fri Feb 23 02:35:15 EST 2024 Tue Aug 26 19:08:46 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | Atorvastatin Healthy volunteers Pneumococcal pneumonia Vaccination Humoral immunity |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c582t-1fcb4e9eb44e66d583a5583a662698c0135eeac816a1411ef23126ac3f8f5fba3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Administrative, technical, or material support: Wildes, Grippin, Fasanya, Dyson, Brantly Study supervision: Brantly These authors contributed equally to this work Study concept and design: Wildes, Grippin, Fasanya, Dyson, Brantly Drafting of the manuscript: Wildes, Fasanya, Grippin Acquisition, analysis and interpretation of data: Wildes, Grippin, Fasanya, Dyson, Brantly Author Contributions Critical revision of the manuscript for important intellectual content: Wildes, Fasanya, Grippin Statistical analysis: Wildes, Grippin, Fasanya, Dyson, Brantly |
| ORCID | 0000-0001-8313-9144 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0264410X19300775 |
| PMID | 30686636 |
| PQID | 2180835292 |
| PQPubID | 105530 |
| PageCount | 12 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6379110 proquest_miscellaneous_2221025598 proquest_miscellaneous_2179473789 proquest_journals_2180835292 pubmed_primary_30686636 crossref_primary_10_1016_j_vaccine_2019_01_023 crossref_citationtrail_10_1016_j_vaccine_2019_01_023 elsevier_sciencedirect_doi_10_1016_j_vaccine_2019_01_023 elsevier_clinicalkey_doi_10_1016_j_vaccine_2019_01_023 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-02-28 |
| PublicationDateYYYYMMDD | 2019-02-28 |
| PublicationDate_xml | – month: 02 year: 2019 text: 2019-02-28 day: 28 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands – name: Kidlington |
| PublicationTitle | Vaccine |
| PublicationTitleAlternate | Vaccine |
| PublicationYear | 2019 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Kolawole, McLeod, Ndaw, Abebayehu, Barnstein, Faber (b0070) 2016; 196 Weinberger, Herndler-Brandstetter, Schwanninger, Weiskopf, Grubeck-Loebenstein (b0030) 2008; 46 Griffin, Zhu, Moore, Whitney, Grijalva (b0010) 2013; 369 Mausner-Fainberg, Luboshits, Mor, Maysel-Auslender, Rubinstein, Keren (b0065) 2008; 197 Maron, Fazio, Linton (b0175) 2000; 101 Manni, Gargaro, Turco, Scalisi, Matino, Pirro (b0185) 2018; 200 Azor, dos Santos, Futata, de Brito, Maruta, Rivitti (b0115) 2011; 166 Vandermeer, Thomas, Kamimoto, Reingold, Gershman, Meek (b0125) 2012; 205 Fehr, Kahlert, Fierz, Joller-Jemelka, Riesen, Rickli (b0060) 2004; 175 Ansell, Navab, Hama, Kamranpour, Fonarow, Hough (b0095) 2003; 108 Chyu, Lio, Dimayuga, Zhou, Zhao, Yano (b0100) 2014; 9 Kantor, Rehm, Haas, Chan, Giovannucci (b0035) 2015; 314 Arora, Chen, Paglia, Gallagher, Allen, Vyas (b0045) 2006; 103 Mitchell, Marette (b0105) 2014; 63 Chou, Dana, Blazina, Daeges, Jeanne (b0120) 2016; 316 Thomsen, Riis, Kornum, Christensen, Johnsen, Sørensen (b0135) 2008; 168 Kuijk, Mandey, Schellens, Waterham, Rijkers, Coffer (b0195) 2008; 45 Majlesi, Samorapoompichit, Hauswirth, Schernthaner, Ghannadan, Baghestanian (b0080) 2003; 73 Lee, Scumpia, Byars, Kelly, Zhuang, Shuster (b0160) 2006; 24 Schramm, Menger, Harder, Schmits, Adam, Weitz-Schmidt (b0180) 2007; 120 O'Brien, Wolfson, Watt, Henkle, Deloria-Knoll, McCall (b0015) 2009; 374 Li, Dudczak, Koller, Baghestanian, Ghannadan, Minar (b0075) 2003; 59 Youssef, Stuve, Patarroyo, Ruiz, Radosevich, Hur (b0050) 2002; 420 Turco, Scalisi, Gargaro, Pirro, Fallarino (b0190) 2017; 198 Vinogradova, Coupland, Hippisley-Cox (b0150) 2011; 61 Zeiser, Youssef, Baker, Kambham, Steinman, Negrin (b0055) 2007; 110 Papazian, Roch, Charles, Penot-Ragon, Perrin, Roulier (b0200) 2013; 310 Feikin, Schuchat, Kolczak, Barrett, Harrison, Lefkowitz (b0005) 2000; 90 Kwak, Mulhaupt, Myit, Mach (b0085) 2000; 6 Uddin, Borrow, Haeney, Moran, Warrington, Balmer (b0170) 2006; 24 Min, Brown, LeGros (b0205) 2012; 135 Jackson, Neuzil, Yu, Benson, Barlow, Adams (b0020) 2003; 348 van de Garde, Hak, Souverein, Hoes, van den Bosch, Leufkens (b0140) 2006; 61 Albert, Danielson, Rifai, Ridker (b0090) 2001; 286 Schlienger, Fedson, Jick, Jick, Meier (b0130) 2007; 27 Orange, Ballow, Stiehm, Ballas, Chinen, De La Morena (b0165) 2012; 130 Adedinsewo, Taka, Agasthi, Sachdeva, Rust, Onwuanyi (b0040) 2016; 39 Kim, Riley, Hunter (b0025) 2018; 168 Chalmers, Singanayagam, Murray, Hill (b0155) 2008; 121 Coward, Marei, Yang, Vasa-Nicotera, Chow (b0110) 2006; 176 Yu, Zhu, Liu, Gao (b0145) 2017; 2017 Uddin (10.1016/j.vaccine.2019.01.023_b0170) 2006; 24 Chyu (10.1016/j.vaccine.2019.01.023_b0100) 2014; 9 Adedinsewo (10.1016/j.vaccine.2019.01.023_b0040) 2016; 39 Zeiser (10.1016/j.vaccine.2019.01.023_b0055) 2007; 110 Youssef (10.1016/j.vaccine.2019.01.023_b0050) 2002; 420 Griffin (10.1016/j.vaccine.2019.01.023_b0010) 2013; 369 Lee (10.1016/j.vaccine.2019.01.023_b0160) 2006; 24 Vandermeer (10.1016/j.vaccine.2019.01.023_b0125) 2012; 205 Majlesi (10.1016/j.vaccine.2019.01.023_b0080) 2003; 73 Chalmers (10.1016/j.vaccine.2019.01.023_b0155) 2008; 121 Ansell (10.1016/j.vaccine.2019.01.023_b0095) 2003; 108 Feikin (10.1016/j.vaccine.2019.01.023_b0005) 2000; 90 Kantor (10.1016/j.vaccine.2019.01.023_b0035) 2015; 314 Arora (10.1016/j.vaccine.2019.01.023_b0045) 2006; 103 Schlienger (10.1016/j.vaccine.2019.01.023_b0130) 2007; 27 Mitchell (10.1016/j.vaccine.2019.01.023_b0105) 2014; 63 Kwak (10.1016/j.vaccine.2019.01.023_b0085) 2000; 6 Vinogradova (10.1016/j.vaccine.2019.01.023_b0150) 2011; 61 Orange (10.1016/j.vaccine.2019.01.023_b0165) 2012; 130 Maron (10.1016/j.vaccine.2019.01.023_b0175) 2000; 101 Azor (10.1016/j.vaccine.2019.01.023_b0115) 2011; 166 Kuijk (10.1016/j.vaccine.2019.01.023_b0195) 2008; 45 Jackson (10.1016/j.vaccine.2019.01.023_b0020) 2003; 348 Chou (10.1016/j.vaccine.2019.01.023_b0120) 2016; 316 Schramm (10.1016/j.vaccine.2019.01.023_b0180) 2007; 120 Kolawole (10.1016/j.vaccine.2019.01.023_b0070) 2016; 196 Thomsen (10.1016/j.vaccine.2019.01.023_b0135) 2008; 168 van de Garde (10.1016/j.vaccine.2019.01.023_b0140) 2006; 61 Coward (10.1016/j.vaccine.2019.01.023_b0110) 2006; 176 Papazian (10.1016/j.vaccine.2019.01.023_b0200) 2013; 310 Weinberger (10.1016/j.vaccine.2019.01.023_b0030) 2008; 46 Albert (10.1016/j.vaccine.2019.01.023_b0090) 2001; 286 Yu (10.1016/j.vaccine.2019.01.023_b0145) 2017; 2017 Min (10.1016/j.vaccine.2019.01.023_b0205) 2012; 135 Fehr (10.1016/j.vaccine.2019.01.023_b0060) 2004; 175 Mausner-Fainberg (10.1016/j.vaccine.2019.01.023_b0065) 2008; 197 O'Brien (10.1016/j.vaccine.2019.01.023_b0015) 2009; 374 Li (10.1016/j.vaccine.2019.01.023_b0075) 2003; 59 Kim (10.1016/j.vaccine.2019.01.023_b0025) 2018; 168 Manni (10.1016/j.vaccine.2019.01.023_b0185) 2018; 200 Turco (10.1016/j.vaccine.2019.01.023_b0190) 2017; 198 |
| References_xml | – volume: 108 start-page: 2751 year: 2003 end-page: 2756 ident: b0095 article-title: Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment publication-title: Circulation – volume: 374 start-page: 893 year: 2009 end-page: 902 ident: b0015 article-title: Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates publication-title: Lancet (London, England) – volume: 198 start-page: 67.10 year: 2017 ident: b0190 article-title: Aryl hydrocarbon receptor: a novel target for the anti-inflammatory activity of statin therapy publication-title: J Immunol – volume: 168 start-page: 2081 year: 2008 end-page: 2087 ident: b0135 article-title: Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29 900 patients publication-title: Arch Intern Med – volume: 2017 start-page: 5642704 year: 2017 ident: b0145 article-title: Effect of prior atorvastatin treatment on the frequency of hospital acquired pneumonia and evolution of biomarkers in patients with acute ischemic stroke: a multicenter prospective study publication-title: Biomed Res Int – volume: 286 start-page: 64 year: 2001 end-page: 70 ident: b0090 article-title: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study publication-title: JAMA – volume: 130 start-page: S1 year: 2012 end-page: S24 ident: b0165 article-title: Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the basic and clinical immunology interest section of the American academy of allergy, asthma & immunology publication-title: J Allergy Clin Immunol – volume: 73 start-page: 107 year: 2003 end-page: 117 ident: b0080 article-title: Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3 publication-title: J Leukoc Biol – volume: 61 start-page: 957 year: 2006 end-page: 961 ident: b0140 article-title: Statin treatment and reduced risk of pneumonia in patients with diabetes publication-title: Thorax – volume: 61 start-page: e742 year: 2011 end-page: e748 ident: b0150 article-title: Risk of pneumonia in patients taking statins: population-based nested case-control study publication-title: British J Gen Pract: J Royal College Gen Pract – volume: 39 start-page: 491 year: 2016 end-page: 496 ident: b0040 article-title: Prevalence and factors associated with statin use among a nationally representative sample of US adults: national health and nutrition examination survey, 2011–2012 publication-title: Clin Cardiol – volume: 110 start-page: 4588 year: 2007 end-page: 4598 ident: b0055 article-title: Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity publication-title: Blood – volume: 6 start-page: 1399 year: 2000 end-page: 1402 ident: b0085 article-title: Statins as a newly recognized type of immunomodulator publication-title: Nat Med – volume: 90 start-page: 223 year: 2000 end-page: 229 ident: b0005 article-title: Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997 publication-title: Am J Public Health – volume: 63 start-page: 3569 year: 2014 end-page: 3571 ident: b0105 article-title: Statin-induced insulin resistance through inflammasome activation: sailing between Scylla and Charybdis publication-title: Diabetes – volume: 45 start-page: 2158 year: 2008 end-page: 2165 ident: b0195 article-title: Statin synergizes with LPS to induce IL-1beta release by THP-1 cells through activation of caspase-1 publication-title: Mol Immunol – volume: 166 start-page: 291 year: 2011 end-page: 298 ident: b0115 article-title: Statin effects on regulatory and proinflammatory factors in chronic idiopathic urticaria publication-title: Clin Exp Immunol – volume: 310 start-page: 1692 year: 2013 end-page: 1700 ident: b0200 article-title: Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial publication-title: JAMA – volume: 46 start-page: 1078 year: 2008 end-page: 1084 ident: b0030 article-title: Biology of immune responses to vaccines in elderly persons publication-title: Clin Infect Dis – volume: 175 start-page: 83 year: 2004 end-page: 90 ident: b0060 article-title: Statin-induced immunomodulatory effects on human T cells in vivo publication-title: Atherosclerosis – volume: 205 start-page: 13 year: 2012 end-page: 19 ident: b0125 article-title: Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study publication-title: J Infect Dis – volume: 120 start-page: 315 year: 2007 end-page: 324 ident: b0180 article-title: Statins inhibit lymphocyte homing to peripheral lymph nodes publication-title: Immunology – volume: 121 start-page: e1 year: 2008 ident: b0155 article-title: Prior statin use is associated with improved outcomes in community-acquired pneumonia publication-title: Am J Med – volume: 103 start-page: 7777 year: 2006 end-page: 7782 ident: b0045 article-title: Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells publication-title: Proc Natl Acad Sci – volume: 24 start-page: 5637 year: 2006 end-page: 5644 ident: b0170 article-title: Total and serotype-specific pneumococcal antibody titres in children with normal and abnormal humoral immunity publication-title: Vaccine – volume: 27 start-page: 325 year: 2007 end-page: 332 ident: b0130 article-title: Statins and the risk of pneumonia: a population-based, nested case-control study publication-title: Pharmacotherapy – volume: 316 start-page: 2008 year: 2016 end-page: 2024 ident: b0120 article-title: Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force publication-title: JAMA – volume: 197 start-page: 829 year: 2008 end-page: 839 ident: b0065 article-title: The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells publication-title: Atherosclerosis – volume: 59 start-page: 507 year: 2003 end-page: 516 ident: b0075 article-title: Effect of statins on lipoprotein receptor expression in cell lines from human mast cells and basophils publication-title: Eur J Clin Pharmacol – volume: 9 start-page: e92095 year: 2014 ident: b0100 article-title: Cholesterol lowering modulates T cell function in vivo and in vitro publication-title: PLoS ONE – volume: 176 start-page: 5284 year: 2006 end-page: 5292 ident: b0110 article-title: Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes publication-title: J Immunol – volume: 348 start-page: 1747 year: 2003 end-page: 1755 ident: b0020 article-title: Effectiveness of pneumococcal polysaccharide vaccine in older adults publication-title: N Engl J Med – volume: 200 start-page: 167.19-.19 year: 2018 ident: b0185 article-title: Statins regulates inflammatory macrophage phenotype through the activation of AhR publication-title: J Immunol – volume: 196 start-page: 1461 year: 2016 end-page: 1470 ident: b0070 article-title: Fluvastatin suppresses mast cell and basophil IgE responses: genotype-dependent effects publication-title: J Immunol – volume: 135 start-page: 192 year: 2012 end-page: 197 ident: b0205 article-title: Understanding the roles of basophils: breaking dawn publication-title: Immunology – volume: 168 start-page: 210 year: 2018 end-page: 220 ident: b0025 article-title: Advisory committee on immunization p. recommended immunization schedule for adults aged 19 years or older, United States, 2018 publication-title: Ann Intern Med – volume: 420 start-page: 78 year: 2002 end-page: 84 ident: b0050 article-title: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease publication-title: Nature – volume: 369 start-page: 155 year: 2013 end-page: 163 ident: b0010 article-title: hospitalizations for pneumonia after a decade of pneumococcal vaccination publication-title: N Engl J Med – volume: 314 start-page: 1818 year: 2015 end-page: 1831 ident: b0035 article-title: Trends in prescription drug use among adults in the United States From 1999–2012 publication-title: JAMA – volume: 24 start-page: 4035 year: 2006 end-page: 4040 ident: b0160 article-title: Short-term atorvastatin treatment enhances specific antibody production following tetanus toxoid vaccination in healthy volunteers publication-title: Vaccine – volume: 101 start-page: 207 year: 2000 end-page: 213 ident: b0175 article-title: Current perspectives on statins publication-title: Circulation – volume: 27 start-page: 325 year: 2007 ident: 10.1016/j.vaccine.2019.01.023_b0130 article-title: Statins and the risk of pneumonia: a population-based, nested case-control study publication-title: Pharmacotherapy doi: 10.1592/phco.27.3.325 – volume: 205 start-page: 13 year: 2012 ident: 10.1016/j.vaccine.2019.01.023_b0125 article-title: Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study publication-title: J Infect Dis doi: 10.1093/infdis/jir695 – volume: 166 start-page: 291 year: 2011 ident: 10.1016/j.vaccine.2019.01.023_b0115 article-title: Statin effects on regulatory and proinflammatory factors in chronic idiopathic urticaria publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.2011.04473.x – volume: 314 start-page: 1818 year: 2015 ident: 10.1016/j.vaccine.2019.01.023_b0035 article-title: Trends in prescription drug use among adults in the United States From 1999–2012 publication-title: JAMA doi: 10.1001/jama.2015.13766 – volume: 6 start-page: 1399 year: 2000 ident: 10.1016/j.vaccine.2019.01.023_b0085 article-title: Statins as a newly recognized type of immunomodulator publication-title: Nat Med doi: 10.1038/82219 – volume: 286 start-page: 64 year: 2001 ident: 10.1016/j.vaccine.2019.01.023_b0090 article-title: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study publication-title: JAMA doi: 10.1001/jama.286.1.64 – volume: 120 start-page: 315 year: 2007 ident: 10.1016/j.vaccine.2019.01.023_b0180 article-title: Statins inhibit lymphocyte homing to peripheral lymph nodes publication-title: Immunology doi: 10.1111/j.1365-2567.2006.02505.x – volume: 39 start-page: 491 year: 2016 ident: 10.1016/j.vaccine.2019.01.023_b0040 article-title: Prevalence and factors associated with statin use among a nationally representative sample of US adults: national health and nutrition examination survey, 2011–2012 publication-title: Clin Cardiol doi: 10.1002/clc.22577 – volume: 200 start-page: 167.19-.19 year: 2018 ident: 10.1016/j.vaccine.2019.01.023_b0185 article-title: Statins regulates inflammatory macrophage phenotype through the activation of AhR publication-title: J Immunol doi: 10.4049/jimmunol.200.Supp.167.19 – volume: 198 start-page: 67.10 year: 2017 ident: 10.1016/j.vaccine.2019.01.023_b0190 article-title: Aryl hydrocarbon receptor: a novel target for the anti-inflammatory activity of statin therapy publication-title: J Immunol doi: 10.4049/jimmunol.198.Supp.67.10 – volume: 175 start-page: 83 year: 2004 ident: 10.1016/j.vaccine.2019.01.023_b0060 article-title: Statin-induced immunomodulatory effects on human T cells in vivo publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2004.02.016 – volume: 63 start-page: 3569 year: 2014 ident: 10.1016/j.vaccine.2019.01.023_b0105 article-title: Statin-induced insulin resistance through inflammasome activation: sailing between Scylla and Charybdis publication-title: Diabetes doi: 10.2337/db14-1059 – volume: 110 start-page: 4588 year: 2007 ident: 10.1016/j.vaccine.2019.01.023_b0055 article-title: Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity publication-title: Blood doi: 10.1182/blood-2007-08-106005 – volume: 121 start-page: e1 issue: 1002–7 year: 2008 ident: 10.1016/j.vaccine.2019.01.023_b0155 article-title: Prior statin use is associated with improved outcomes in community-acquired pneumonia publication-title: Am J Med – volume: 374 start-page: 893 year: 2009 ident: 10.1016/j.vaccine.2019.01.023_b0015 article-title: Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates publication-title: Lancet (London, England) doi: 10.1016/S0140-6736(09)61204-6 – volume: 2017 start-page: 5642704 year: 2017 ident: 10.1016/j.vaccine.2019.01.023_b0145 article-title: Effect of prior atorvastatin treatment on the frequency of hospital acquired pneumonia and evolution of biomarkers in patients with acute ischemic stroke: a multicenter prospective study publication-title: Biomed Res Int doi: 10.1155/2017/5642704 – volume: 61 start-page: e742 year: 2011 ident: 10.1016/j.vaccine.2019.01.023_b0150 article-title: Risk of pneumonia in patients taking statins: population-based nested case-control study publication-title: British J Gen Pract: J Royal College Gen Pract doi: 10.3399/bjgp11X606654 – volume: 168 start-page: 210 year: 2018 ident: 10.1016/j.vaccine.2019.01.023_b0025 article-title: Advisory committee on immunization p. recommended immunization schedule for adults aged 19 years or older, United States, 2018 publication-title: Ann Intern Med doi: 10.7326/M17-3439 – volume: 130 start-page: S1 year: 2012 ident: 10.1016/j.vaccine.2019.01.023_b0165 article-title: Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the basic and clinical immunology interest section of the American academy of allergy, asthma & immunology publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2012.07.002 – volume: 103 start-page: 7777 year: 2006 ident: 10.1016/j.vaccine.2019.01.023_b0045 article-title: Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.0508492103 – volume: 197 start-page: 829 year: 2008 ident: 10.1016/j.vaccine.2019.01.023_b0065 article-title: The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2007.07.031 – volume: 46 start-page: 1078 year: 2008 ident: 10.1016/j.vaccine.2019.01.023_b0030 article-title: Biology of immune responses to vaccines in elderly persons publication-title: Clin Infect Dis doi: 10.1086/529197 – volume: 61 start-page: 957 year: 2006 ident: 10.1016/j.vaccine.2019.01.023_b0140 article-title: Statin treatment and reduced risk of pneumonia in patients with diabetes publication-title: Thorax doi: 10.1136/thx.2006.062885 – volume: 196 start-page: 1461 year: 2016 ident: 10.1016/j.vaccine.2019.01.023_b0070 article-title: Fluvastatin suppresses mast cell and basophil IgE responses: genotype-dependent effects publication-title: J Immunol doi: 10.4049/jimmunol.1501932 – volume: 24 start-page: 4035 year: 2006 ident: 10.1016/j.vaccine.2019.01.023_b0160 article-title: Short-term atorvastatin treatment enhances specific antibody production following tetanus toxoid vaccination in healthy volunteers publication-title: Vaccine doi: 10.1016/j.vaccine.2005.12.042 – volume: 45 start-page: 2158 year: 2008 ident: 10.1016/j.vaccine.2019.01.023_b0195 article-title: Statin synergizes with LPS to induce IL-1beta release by THP-1 cells through activation of caspase-1 publication-title: Mol Immunol doi: 10.1016/j.molimm.2007.12.008 – volume: 348 start-page: 1747 year: 2003 ident: 10.1016/j.vaccine.2019.01.023_b0020 article-title: Effectiveness of pneumococcal polysaccharide vaccine in older adults publication-title: N Engl J Med doi: 10.1056/NEJMoa022678 – volume: 73 start-page: 107 year: 2003 ident: 10.1016/j.vaccine.2019.01.023_b0080 article-title: Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3 publication-title: J Leukoc Biol doi: 10.1189/jlb.0202075 – volume: 108 start-page: 2751 year: 2003 ident: 10.1016/j.vaccine.2019.01.023_b0095 article-title: Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment publication-title: Circulation doi: 10.1161/01.CIR.0000103624.14436.4B – volume: 9 start-page: e92095 year: 2014 ident: 10.1016/j.vaccine.2019.01.023_b0100 article-title: Cholesterol lowering modulates T cell function in vivo and in vitro publication-title: PLoS ONE doi: 10.1371/journal.pone.0092095 – volume: 135 start-page: 192 year: 2012 ident: 10.1016/j.vaccine.2019.01.023_b0205 article-title: Understanding the roles of basophils: breaking dawn publication-title: Immunology doi: 10.1111/j.1365-2567.2011.03530.x – volume: 24 start-page: 5637 year: 2006 ident: 10.1016/j.vaccine.2019.01.023_b0170 article-title: Total and serotype-specific pneumococcal antibody titres in children with normal and abnormal humoral immunity publication-title: Vaccine doi: 10.1016/j.vaccine.2006.03.088 – volume: 90 start-page: 223 year: 2000 ident: 10.1016/j.vaccine.2019.01.023_b0005 article-title: Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997 publication-title: Am J Public Health doi: 10.2105/AJPH.90.2.223 – volume: 101 start-page: 207 year: 2000 ident: 10.1016/j.vaccine.2019.01.023_b0175 article-title: Current perspectives on statins publication-title: Circulation doi: 10.1161/01.CIR.101.2.207 – volume: 310 start-page: 1692 year: 2013 ident: 10.1016/j.vaccine.2019.01.023_b0200 article-title: Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2013.280031 – volume: 59 start-page: 507 year: 2003 ident: 10.1016/j.vaccine.2019.01.023_b0075 article-title: Effect of statins on lipoprotein receptor expression in cell lines from human mast cells and basophils publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-003-0668-1 – volume: 420 start-page: 78 year: 2002 ident: 10.1016/j.vaccine.2019.01.023_b0050 article-title: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease publication-title: Nature doi: 10.1038/nature01158 – volume: 176 start-page: 5284 year: 2006 ident: 10.1016/j.vaccine.2019.01.023_b0110 article-title: Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes publication-title: J Immunol doi: 10.4049/jimmunol.176.9.5284 – volume: 168 start-page: 2081 year: 2008 ident: 10.1016/j.vaccine.2019.01.023_b0135 article-title: Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29 900 patients publication-title: Arch Intern Med doi: 10.1001/archinte.168.19.2081 – volume: 369 start-page: 155 year: 2013 ident: 10.1016/j.vaccine.2019.01.023_b0010 article-title: hospitalizations for pneumonia after a decade of pneumococcal vaccination publication-title: N Engl J Med doi: 10.1056/NEJMoa1209165 – volume: 316 start-page: 2008 year: 2016 ident: 10.1016/j.vaccine.2019.01.023_b0120 article-title: Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force publication-title: JAMA doi: 10.1001/jama.2015.15629 |
| SSID | ssj0005319 |
| Score | 2.314462 |
| Snippet | •First trial on the impact of statins on pneumococcal polysaccharide vaccination.•Atorvastatin enhanced total pneumococcal-specific antibody response by... The immunomodulatory effects of statins on vaccine response remain uncertain. Therefore, the objective of this study was to determine if atorvastatin enhances... BackgroundThe immunomodulatory effects of statins on vaccine response remain uncertain. Therefore, the objective of this study was to determine if atorvastatin... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1313 |
| SubjectTerms | adjuvants analysis of variance antibodies Atorvastatin blood serum Body mass index Clinical trials cohort studies Consent Control methods Cytokines Erythrocyte sedimentation rate Erythrocytes Healthy volunteers Humoral immunity Immune response Immune response (humoral) Immune system Immunogenicity Immunomodulation immunomodulators Infections Informed consent Lactose Lymphocytes Lymphocytes T Medical screening Mortality patients Pneumococcal pneumonia Pneumonia Polysaccharides Population studies randomized clinical trials Seroconversion Statins Tetanus Vaccination Vaccines Variance analysis volunteers women |
| SummonAdditionalLinks | – databaseName: ScienceDirect Freedom Collection Journals dbid: AIKHN link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Rb9NADLZGJxAvCAqMwkBGQnta1iSXuyS8TRNTAW2axDb1LUpyFy3TllRrO1H-Dn8UO5e0FARDvFRpz04vjmP7cv5sgHcZryokLUu8MI-dQBvhZK6RdOTqyI8j5WrGDh8dq9FZ8Gksxxtw0GFhOK2ytf3WpjfWuv1l2EpzOCnL4Re38eXumEKQppDbPdj0RaxkDzb3P34eHa8yPUTT34PpHWZYAXmGl3u3ac472JzkFdsCnuJPLur3EPTXTMqfXNPhY3jUxpS4b6f9BDZM1Yf7tsvkog8Pjtr98z7snNhK1YtdPF0Br6a7uIMnqxrWxNM_5zSZBquLHftT-G5rHWNdIK_Vb1OGI5UV1hVezK8Z648l400M3tjUW4OzGn3hkDrT1HFSGSIjE0yKgZP6ajElsdD_ltqglVCjJ0intPjMBbL1pHtPQep7njJycHyefkVysbq-Lr8ZjR24E5sOJM_g7PDD6cHIabs8OLmM_JnjFXkWmNhkQWCU0jISqeQPRUutOMopRJWGvEPkqdQLPM8UFJH6Ks1FERWyyFLxHHpVXZkXgLGgcZ3laZTJoBCSjkQW-Fq6hasDHQ4g6G5skrcl0LkTx1XS5bpdJq0-JKwPieslpA8D2FuyTWwNkLsYVKc1SScDMskJeam7GKMl49pT8C-s2516Jq0ZmiYUvzUhduwP4O1ymAwI7wqllannTEMmORRhFP-Fxuc3A1zLfwBbVuOXkhAMMlJCDSBcexaWBFzAfH2kKi-aQuZKhORr3Zf_f9Wv4CF9821S4Db0Zjdz85qixFn2prUCPwASDGvU priority: 102 providerName: Elsevier |
| Title | Effect of atorvastatin on humoral immune response to 23-valent pneumococcal polysaccharide vaccination in healthy volunteers: The StatVax randomized clinical trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X19300775 https://dx.doi.org/10.1016/j.vaccine.2019.01.023 https://www.ncbi.nlm.nih.gov/pubmed/30686636 https://www.proquest.com/docview/2180835292 https://www.proquest.com/docview/2179473789 https://www.proquest.com/docview/2221025598 https://pubmed.ncbi.nlm.nih.gov/PMC6379110 |
| Volume | 37 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1fb9MwELfYJhAvCAqMwpgOCe1p2ZL4Txxe0Jg2FdCqCm1T36IkdrROW1LWdqI88GX4otzFSctAbLwkluxLXft8d7bvfsfY24x2FRK3JUGUx54wlnuZbyWWfKPDWCvfUOzwUV_1TsSnoRw2B26Txq2ylYm1oDZVTmfku6iKamshDt-Pv3qUNYpuV5sUGitsrYYuQ36OhtHSxYPXiT1wmyE8EfjDZQTP7vnOdZrT1TV5d8UOuZP_Szf9bXv-6UL5m046fMweNcYk7LnZf8Lu2bLD7rv0kvMOe3DUXJx32NbAQVTPt-F4GXE12YYtGCzBq5Gmc0r-MXWQLrTkT9lPB3IMVQG0Sb9OKQ5pVEJVwtnskoL8YUSBJhaunM-thWkFIfeQj7HrMC4tNkPZixwB4-piPsFhwd8dGQtuhGoGAfykC8ycA4lNnHS0Tt9Rl4Gs4tP0G6BuNdXl6Ls10EZ1Qp165Bk7OTw43u95TXoHL5c6nHpBkWfCxjYTwiplpOappIfCPVasc7RNpUW1oAOVBiIIbIGmaKjSnBe6kEWW8udstaxK-4JBzLHeZHmqMykKLrHEMxEa6Re-ESbqMtFObJI32OeUguMiaZ3czpOGHxLih8QPEuSHLttZkI0d-MddBKrlmqQdA5TFCaqnuwj1grAxfZxJ8z-kGy17Jo38mSTL1dJlbxbVKDnoOigtbTWjNiiLIx7p-JY2IR0JEIh_l607jl-MBKfoIsVVl0U31sKiASGX36wpR2c1grniESpZ_-XtXX_FHtL_dAACG2x1ejWzr9EEnGabbGXnR7BZr3Z86n0sr-19_Nzr4_vDQX_w5RcOlGVQ |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGJz5eEBQGhQGHBHtatiR2nAQJIT42dWytKtRNfQtJ7GidtqSs7aD8O7zzN3IXJy0DsfGylyqSfaljn88_2_e7Y-xFQrsKD7cljp-GllCaW4mtPXyyVeCGgbQVcYc7XdneFx8H3mCJ_ay5MORWWdvE0lCrIqUz8k1cikq0ELpvRl8syhpFt6t1Cg2jFrt69hW3bOPXOx9wfF-67vZW_33bqrIKWKkXuBPLydJE6FAnQmgplRfw2KMfidA-DFKERJ5GaxQ4MnaE4-gMEZAr45RnQeZlSczxvdfYsiBGa4Mtv9vq9j4tnEp4mUoENzbCEo49WHCGNo82zuKULsvJnyw0sUL5v1bDv9Hun06bv62C23fY7Qq-wlujb3fZks6b7LpJaDlrshud6qq-ydZ6Jij2bB36C47XeB3WoLcIl40yzQPyyClpwVCL32M_TFhlKDKgY4GzmJhPwxyKHA6nJxRWAIZEbdFwarx8NUwKcLmFMwebDqNcYzW09qiDMCqOZ2PsFvzfodJgeqhUScBXGiroDMhQo5ohHn5FTQbC4QfxN8DVXBUnw-9aQc0jhTLZyX22fyVDv8IaeZHrhwxCjuUqSeMg8UTGPXziiXCVZ2e2EspvMVEPbJRW0dYp6cdxVLvVHUWVPkSkD5HtRKgPLbYxFxuZcCOXCchaa6K6D9D6R7ggXiYYzAUrsGVA1P-IrtbqGVUWbxwt5meLPZ8Xo62iC6g418WU6qD197kfhBfUcekQgtIGtNgDo_HznuDEZ5Jctph_bi7MK1Cs9PMl-fCwjJkuuY_Luv3o4qY_Yzfb_c5etLfT3X3MbtE3m_AFq6wxOZ3qJwhAJ8nTatYD-3zVhuYXKPWe0A |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGEBMvE5RbYcBBgj0taxJfkiAhhBjVxtjUh23qW5bEjtZpS7q1HZS_w7_g13FOnLQMxMbLXqpI9kkd-1w-2-fC2OuUdhUStyVekEWO0IY7qWskPrk69KNQuZpih3d21ea--NyX_QX2s4mFIbfKRidWilqXGZ2Rd9AUVWgh8jt57RbR2-i-H545VEGKblqbchqWRbbN9Ctu30bvtjZwrd_4fvfT3sdNp64w4GQy9MeOl2epMJFJhTBKaRnyRNKPQpgfhRnCI2lQM4WeSjzheSZHNOSrJON5mMs8TTi-9xa7HXBEVShLQT-Yu5fwqqgIbnGEIzy3P48e6hyvXyQZXZuTZ1lks4byf9nFv3Hvn-6bv9nD7j22XANZ-GA57z5bMEWL3bGlLacttrRTX9q32GrPpseersHePNprtAar0Jsnzkaa1gH55lQBwtCQP2A_bIJlKHOgA4KLhGKgBgWUBRxNTinBAAwoyMXAufX3NTAuwecOyhAOHYaFwW6o95EbYVieTEc4Lfi_A23AzlDFnICvtEGhUyCVjQyHyPgtDRkIkR8k3wDtui5PB9-NhiaiFKqyJw_Z_o0s_CO2WJSFecIg4tiu0ywJUylyLvGJp8LX0s1dLXTQZqJZ2Dir865T-Y-TuHGwO45rfoiJH2LXi5Ef2mx9Rja0iUeuI1AN18TNHKAdiNE0XkcYzghr2GXh1P-QrjTsGde6bxTPJbXNXs2aUWvRVVRSmHJCfdAOBDwIoyv6-HQcQQUE2uyx5fjZTHCKbFJctVlwSRZmHShr-uWWYnBUZU9XPEAD7z69eugv2RKql_jL1u72M3aXPtnmMVhhi-PziXmOSHScvqhEHtjhTeuYX0KGoZc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+atorvastatin+on+humoral+immune+response+to+23-valent+pneumococcal+polysaccharide+vaccination+in+healthy+volunteers%3A+The+StatVax+randomized+clinical+trial&rft.jtitle=Vaccine&rft.au=Wildes%2C+Tyler+J.&rft.au=Grippin%2C+Adam&rft.au=Fasanya%2C+Henrietta&rft.au=Dyson%2C+Kyle+A.&rft.date=2019-02-28&rft.issn=0264-410X&rft.volume=37&rft.issue=10&rft.spage=1313&rft.epage=1324&rft_id=info:doi/10.1016%2Fj.vaccine.2019.01.023&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_vaccine_2019_01_023 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0264-410X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0264-410X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0264-410X&client=summon |